A third of the world’s people are infected with tuberculosis, and someone new is infected every second. TB is notoriously hard to treat, requiring a course of multiple antibiotics over six to nine months. Many people don’t complete the full course of treatment, which leads to increasing antibiotic resistance against the disease.
Researchers at the Albert Einstein College of Medicine of Yeshiva University have synthesized chemicals that are up to 10 times more effective than isoniazid, the leading anti-tuberculosis drug.
In a finding that could lead to better methods for preventing tuberculosis, researchers at the Albert Einstein College of Medicine have helped to solve a nearly century-old medical mystery: What caused the bacteria in the TB vaccine to become weakened and therefore safe for human use? Their findings, published in the October 14th issue of the Proceedings of the National Academy of Sciences, could lead to a better vaccine for treating TB, which kills an estimated two million to three million people worldwide each year. Dr. William Jacobs, the study’s senior author, is a Howard Hughes investigator and professor of microbiology and immunology at Einstein.